Regeneron Pharmaceuticals Inc (LTS:0R2M)
$ 827.21 -6.645 (-0.8%) Market Cap: 91.15 Bil Enterprise Value: 84.05 Bil PE Ratio: 20.53 PB Ratio: 3.11 GF Score: 93/100

Regeneron Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript

Sep 27, 2021 / 01:20PM GMT
Release Date Price: $618.28 (-2.55%)
Alethia Rene Young
Cantor Fitzgerald & Co., Research Division - Director of Equity Research & Head of Healthcare Research

Hi, everybody. It's Alethia Young here. I cover large cap, small mid cap biotech at Cantor. Obviously, this company needs no introduction, but Regeneron. We're actually going to be having a very specific conversation with Regeneron today around their Regeneron Genetics Medicines. I'm very happy to have the RGC leader, Dr. Aris Baras. He's SVP, General Manager at Regeneron Genetic Center and, of course we don't -- Justin doesn't need an introduction, with Justin Holko, he is VP of IR at Regeneron.

So we are going to do a fireside chat and we'll just dive right in, so --

Justin Holko;Alethia Rene Young
Regeneron Pharmaceuticals, Inc. - VP of IR;Cantor Fitzgerald & Co., Research Division - Director of Equity Research

Alethia, maybe before we jump in, if I could just give the quick forward-looking statement. And then I think Aris has a couple of points, he'd probably like to jump in with.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot